TET2 and acute myeloid leukemia: performed NGS with a targeted gene panel (including FLT3-ITD, DNMT3A, TET2, PTPN11) in 104 AML patients at day 21 post-transplantation, and they observed that patients with VAF post-HSCT (≥0.2%) had increased relapse incidence (56.2% vs 16.0%, P < 0.001).